Barzegar S, Rezvani MR, Safa M, Amani A, Abbaspour A, Pourfathollah A, et al
Like liraglutide, it is a GLP-1-only agonist
Many patients report subjective improvements in energy levels after initiating GLP-1 therapy, though this effect is not universal and reflects multiple contributing factors rather than direct pharmacological stimulation
We also recommend studies to evaluate the potential side effects of taking semaglutide long-term among those with obesity or diabetes, as well as other at-risk populations, she says
Medication Storage Appropriateness in US Households
Which mechanisms of action have demonstrated efficacy in obesitys common comorbidities